CA2858984C - Use of c1-inhibitor for the treatment of secondary edema of the central nervous system - Google Patents

Use of c1-inhibitor for the treatment of secondary edema of the central nervous system Download PDF

Info

Publication number
CA2858984C
CA2858984C CA2858984A CA2858984A CA2858984C CA 2858984 C CA2858984 C CA 2858984C CA 2858984 A CA2858984 A CA 2858984A CA 2858984 A CA2858984 A CA 2858984A CA 2858984 C CA2858984 C CA 2858984C
Authority
CA
Canada
Prior art keywords
inhibitor
edema
brain
use according
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2858984A
Other languages
English (en)
French (fr)
Other versions
CA2858984A1 (en
Inventor
Christoph Kleinschnitz
Marc Nolte
Guido Stoll
Gerhard Dickneite
Stefan Schulte
Bernhard Nieswandt
Ingo Pragst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of CA2858984A1 publication Critical patent/CA2858984A1/en
Application granted granted Critical
Publication of CA2858984C publication Critical patent/CA2858984C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2858984A 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system Active CA2858984C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11195254.5 2011-12-22
EP11195254 2011-12-22
US201261587371P 2012-01-17 2012-01-17
US61/587,371 2012-01-17
PCT/EP2012/076691 WO2013093027A1 (en) 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system

Publications (2)

Publication Number Publication Date
CA2858984A1 CA2858984A1 (en) 2013-06-27
CA2858984C true CA2858984C (en) 2021-01-05

Family

ID=48667767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2858984A Active CA2858984C (en) 2011-12-22 2012-12-21 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system

Country Status (10)

Country Link
US (1) US9452203B2 (enExample)
EP (1) EP2793935B1 (enExample)
JP (1) JP6127063B2 (enExample)
KR (1) KR102022231B1 (enExample)
CN (1) CN104080474B (enExample)
AU (1) AU2012318275B2 (enExample)
CA (1) CA2858984C (enExample)
DK (1) DK2793935T3 (enExample)
ES (1) ES2587863T3 (enExample)
WO (1) WO2013093027A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
SMT201700415T1 (it) 2013-03-15 2017-11-15 Shire Viropharma Inc Composizioni di c1-inh per l’uso nella prevenzione e nel trattamento dell’angioedema ereditario (hae)
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
WO2016081889A1 (en) * 2014-11-21 2016-05-26 Kurt Baekgaard Osther Recombinant c1 esterase inhibitor and use thereof
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
JP7189767B2 (ja) 2015-11-19 2022-12-14 武田薬品工業株式会社 組換えヒトｃ１エステラーゼインヒビター及びその使用
CN116554320A (zh) 2016-10-12 2023-08-08 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4227762A1 (de) 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
JP3941174B2 (ja) 1996-08-26 2007-07-04 富士ゼロックス株式会社 複合材料及びその製造方法
AU6083899A (en) 1999-09-16 2001-04-17 Aventis Behring Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
SI2380587T1 (en) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Use of a C1 inhibitor to prevent ischemic reperfusion injury
CN101365478B (zh) * 2005-12-21 2016-06-22 法明知识产权股份有限公司 C1抑制剂在预防缺血-再灌注损伤中的应用

Also Published As

Publication number Publication date
EP2793935B1 (en) 2016-05-25
CN104080474A (zh) 2014-10-01
KR102022231B1 (ko) 2019-09-19
AU2012318275A1 (en) 2013-07-11
CN104080474B (zh) 2016-04-27
HK1201729A1 (zh) 2015-09-11
US20140371425A1 (en) 2014-12-18
ES2587863T3 (es) 2016-10-27
JP6127063B2 (ja) 2017-05-10
AU2012318275B2 (en) 2016-05-19
KR20140107567A (ko) 2014-09-04
DK2793935T3 (en) 2016-09-05
CA2858984A1 (en) 2013-06-27
EP2793935A1 (en) 2014-10-29
JP2015502389A (ja) 2015-01-22
US9452203B2 (en) 2016-09-27
WO2013093027A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CA2858984C (en) Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
Göb et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation
Kraft et al. The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood–brain-barrier damage, inflammation and thrombosis
KR101956585B1 (ko) 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법
Mencl et al. FTY720 does not protect from traumatic brain injury in mice despite reducing posttraumatic inflammation
KR20130054953A (ko) 간질성 폐 질환을 치료하기 위한 인자 ｘｉｉ 억제제
JP2015509984A (ja) 子癇前症の治療におけるアンチトロンビンの使用
HK1201729B (en) Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
Cirak et al. The effects of endothelin antagonist BQ-610 on cerebral vascular wall following experimental subarachnoid hemorrhage and cerebral vasospasm
US7375076B2 (en) Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
Wang et al. Protective and detrimental effects of neuroectodermal cell–derived tissue factor in mouse models of stroke
Cao et al. Anti-Angiogenic and Anti-Scarring Dual Effect of Galectin-3 Inhibition in Mouse Models of Corneal Wound Healing
US20250144179A1 (en) Peptide hormone to prevent or treat vasospasm, brain injury or cerebral edema
Tamanna et al. ACE2: A key modulator of RAS and pregnancy
Shanmugaiah et al. The efficacy of intracisternal irrigation of papaverine on cerebral blood flow in patients with subarachnoid hemorrhage
Elkhrbash The role of angiotensin AT1 and AT2 receptors in the development of apoptosis and inflammation following experimental myocardial infarction
US20200062855A1 (en) Compositions and methods of promoting wound healing
Song et al. Up-regulation of TGF-β via the activation of extracellular signal-regulated kinase 1 and 2 induced by prorenin in human renal mesangial cells
US20160008425A1 (en) Therapeutic agent for amniotic fluid embolism
Montazeri-Khosh et al. Post-hemorrhagic hydrocephalus: a neuroinflammatory perspective on CSF hypersecretion and ventricular enlargement
Olde Heuvel et al. Loss of C3 and CD14 reduces region-specific neuroinflammation in a murine polytrauma model
S Hernandes et al. Hernandes et al., 2018. pdf
Revill et al. Ecallantide
Kwon et al. AT1 receptor blocker losartan protects against 1 mechanical ventilation-induced diaphragmatic dysfunction 2 3 4 5
Kwon et al. AT1 receptor blocker losartan protects against 1 mechanical ventilation-induced diaphragmatic dysfunction 2 3 4 Revision# 2 August 31, 2015 5

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171116